INTRODUCTION
============

There is a wide variety of human-made chemicals in the environment. Organic compounds originating from myriad natural processes and industrial sources ([@b1-tr-35-295]) are also ubiquitous in the human environment. Because long-term exposure to some volatile organic compounds may increase the risk of cancer or birth defects, estimation of the exposures to such compounds is a research area that can have a significant positive impact on human health ([@b2-tr-35-295]). Estimation of health risks due to chemical substances has historically followed guidelines on investigatory studies with experimental animals. The general toxicities of industrial chemicals have been extensively investigated by administering repeated oral doses of the chemicals to rodents. Nonetheless, in general, repeated-dose toxicity studies for many chemicals may require significant cost and time. For animal welfare, the current movement has been focused on developing alternative methods such as *in vitro* studies or *in vitro* studies mimmicking on *in vivo* studies.

Recently developed high-throughput *in vitro* screening assays combined with *in silico* computational models might provide suitable alternative methods to conventional animal testing. However, the pharmacokinetics and/or toxicokinetics (including intestinal absorption) of industrial chemicals are not generally considered when evaluating their toxicological potential. Although extensive toxicity databases have been set up worldwide, only a limited numbers of industrial chemicals possess adequate *in vivo* toxicokinetic data related to pharmacokinetic parameters, such as absorption rates, for assessing potential hazards in humans ([@b3-tr-35-295]). This fact highlights the urgent and significant need to develop more efficient and informative tools to determine toxicity.

To interpret toxicity data obtained from high-throughput *in vitro* screening, scientists at the United States regulatory authorities have recommended the inclusion of both dosimetry and exposure data supported by complex multi-compartment pharmacokinetic models using full-scale physiologically based pharmacokinetic (PBPK) modeling ([@b4-tr-35-295],[@b5-tr-35-295]). Furthermore, recent studies have proposed extrapolation of *in vitro* toxicokinetic screening data to predict *in vivo* toxicokinetics based on chemical structure-based properties ([@b6-tr-35-295],[@b7-tr-35-295]). Against this background, our research group established a simplified systematic PBPK modeling with input parameters derived from *in vitro* and *in vivo* data and the literature ([@b8-tr-35-295],[@b9-tr-35-295]). Because of the utility and simplicity, these models could also be used by the regulatory authorities and the industrial researchers for risk assessment.

A five-year project has started in April 2017, sponsored by the Ministry of Economy and Trade Industry in Japan. The aim is to develop a high-accuracy *in silico* hazard prediction system based on toxicity mechanism using accumulated *in vivo* data over the past 40 years under the Chemical Substance Control Law and the results of *in vitro* studies in toxicology, along with artificial intelligence technology and human expertise (AI-based Substance Hazard Integrated Prediction System, <https://ai-ships.net/en/project.html>). In this review, the absorption rates (Caco-2 cell permeability) and estimated plasma/hepatic pharmacokinetics of a variety of chemicals are evaluated as a part of this national project. The pharmacokinetic parameters were estimated using two approaches to model different chemicals orally administered to rats. The models made use of the reported or experimentally determined plasma pharmacokinetics data. If a successful method could be established to derive the *in vivo* absorption parameters of general chemicals from the measured *in vitro* permeability values, it would be of great benefit. Chemical risk assessment involves the prediction of hepatotoxicity, and the simplified PBPK models used here could predict the hepatic as well as the plasma concentrations of drugs and other chemicals after oral ingestion using both forward and reverse dosimetry.

ORAL ABSORPTION OF CHEMICALS AND THEIR HEPATOTOXICITY
=====================================================

The *in vitro* permeability assay is an established method in pharmaceutical research and is based on human models that use Caco-2 colon cancer cell line to estimate the oral absorption of drugs and other substances ([@b10-tr-35-295]--[@b14-tr-35-295]). However, little information is available on the absorbability of industrial chemicals through the mucosa and/or gastrointestinal absorption, which is a necessary step before such chemicals can exert their toxicological potential.

The procedures used for preparing *in vitro* monolayers of human intestinal Caco-2 cells have been described previously ([@b15-tr-35-295]). For experimental use, Caco-2 cells were seeded on permeable polycarbonate membranes at a density of 1.0 × 10^5^ cells/cm^2^ and were cultured for 3--4 weeks. The apparent permeability coefficients (*P*~app~, nm/s) for time-dependent *in vitro* absorption from the apical side of the Caco-2 monolayer \[10 mM 2-morpholinoethanesulfonic acid monohydrate (pH 6.0)\] to the basal side of the Caco-2 monolayer \[10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.4)\] were calculated as described previously ([@b15-tr-35-295]) ([Fig. 1](#f1-tr-35-295){ref-type="fig"}).

To investigate the relevance of pH-dependent Caco-2 monolayer assays in the *in vivo* absorption rate, the relationship was examined between the measured log *P*~app~ values for the drugs and their reported absorbabilities (fraction absorbed, *F*~a~) in humans. To ensure that the substances analyzed exhibited a diversity of chemical structures, the structures defined by 196 chemical descriptors in a chemoinformatics tool were calculated for 50,000 randomly generated molecules in the original chemical space ([@b15-tr-35-295]). To allow visualization, the resulting chemical space underwent projection onto a two-dimensional plane using generative topographic mapping ([Fig. 2](#f2-tr-35-295){ref-type="fig"}). In this figure, closer plots in the chemical space could indicate more similarity in the chemical properties. A wide range of apparent permeability coefficients (*P*~app~) (approximately 10--1,000 nm/s) across human intestinal epithelial Caco-2 cell monolayers was obtained for a diverse range of drugs/industrial chemicals. There was no evident relationship between the apparent permeability coefficients and the location on the chemical space represented by the two-dimensional plane in this study. Under the present conditions, the oral administration no-observed-effect levels (NOEL) given in the Hazard Evaluation Support System Integrated Platform (HESS) in Japan ([@b16-tr-35-295]) and the chemical absorbance rates obtained from *in vitro* cell permeability data were found to be inversely correlated (*r* = −0.88, *p* \< 0.01, n = 27, [Fig. 3](#f3-tr-35-295){ref-type="fig"}).

HEPATIC CONCENTRATIONS OF CHEMICALS AND THEIR TOXICITIES
========================================================

The current study employed two modeling systems, the simple one-compartment model ([Fig. 4A](#f4-tr-35-295){ref-type="fig"}) that was recently recommended by US authorities as a high-throughput toxicokinetic screening tool, and a simplified PBPK model ([Fig. 4B](#f4-tr-35-295){ref-type="fig"}) made up of chemical receptor (gut), metabolizing (liver), and central (main) compartments. Examples of the plasma concentration curves of individual general chemicals estimated by the two models after virtual oral doses were reported previously ([@b8-tr-35-295],[@b17-tr-35-295]--[@b28-tr-35-295]).

The simplified PBPK models were established as previously described ([@b9-tr-35-295],[@b15-tr-35-295]). For some chemicals, a peripheral compartment was used in addition to the central compartment. The general procedure for PBPK modeling is as follows: the octanol-water partition coefficient (log *P*) and the plasma unbound fraction (*f*~u,\ p~) of the general chemicals were estimated *in silico* using Chemdraw and the Simcyp simulator ([@b29-tr-35-295]). The blood-to-plasma concentration ratio (*R*~b~) and the liver-to-plasma concentration ratio (*K*~p,\ h~) were calculated from *f*~u,\ p~ and log *P* values ([@b30-tr-35-295]):
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The physiological values, such as the hepatic blood flow rate (*Q*~h~) in rats (0.853 L/h) were obtained from the literature ([@b31-tr-35-295]). The volume of the systemic circulation (*V*~1~), the absorption rate constant (*k*~a~), and the *in vivo* hepatic intrinsic clearance (*CL*~h,\ int~) were evaluated using nonlinear regression analysis fitting techniques, as described previously ([@b15-tr-35-295]). The renal clearance (*CL*~r~) was set at a minimum value as compared to the hepatic clearance (*CL*~h~). Finally, to perform modeling, the following system of differential equations ([@b8-tr-35-295]) was solved:
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where *X*~g~ and *X*~peripheral~ are the amounts of the chemicals in the gut and peripheral compartments, respectively; *C*~h~ and *C*~b~ are the hepatic and blood chemical concentrations, respectively; *V*~h~ and *V*~1~ are the volumes of the liver and the central compartment, respectively; *F*~a~ and *F*~g~ are availability; *k*~12~ and *k*~21~ are rate constants; and *Q*~h~ is the hepatic blood flow rate of the systemic circulation in the hepatic compartment.

The calculated maximum plasma concentrations and areas under the concentration-time curves (AUC) of 34 diverse chemicals ([@b15-tr-35-295]) and an updated selection of 70 chemicals (unpublished) obtained using the one-compartment models and our simplified PBPK models were found to be consistent (*r* \> 0.95). However, for 53 chemicals as shown in [Table 1](#t1-tr-35-295){ref-type="table"} ([@b15-tr-35-295]) \[and an updated selection of 70 chemicals (unpublished)\], there were only approximate correlations (*r =* \~0.4--0.6) between the hepatic and plasma concentrations and AUC values ([@b15-tr-35-295]) as estimated using our PBPK model. Moreover, the liver and plasma concentrations of the tested chemicals estimated by the PBPK models differed considerably from the reported empirical values.

Among the compounds with a broad diversity of structures that were used in the PBPK modeling, seven had reported hepatoxicity NOEL or lowest-observed-effect level (LOEL) values in the HESS database ([Table 2](#t2-tr-35-295){ref-type="table"}) ([@b16-tr-35-295]). The LOEL values in rats for oral administrations of 2-mercaptobenzimidazole (CAS No. 583-39-1), 4-nonylphenol (84852-15-3), paraacetaldehyde (123-63-7), 1,2,3-trimethylbenzene (526-73-8), 1,2,4-trimethylbenzene (95-63-6), *m*-cresol (108-39-4), and bisphenol A (80-05-7) were of the order of 10, 250, 300, 300, 300, 300, and 600 mg/kg/day, respectively. The main PBPK model parameters, namely, absorption rate constants, distribution volumes, and hepatic intrinsic clearance values, for these seven compounds are shown in [Table 2](#t2-tr-35-295){ref-type="table"}. Among the simple PBPK modeling results shown in [Table 2](#t2-tr-35-295){ref-type="table"} for virtual oral administration of 1.0 mg/kg to rats, the highest values for the maximum plasma concentration and AUC were observed for paraacetaldehyde (1,070 ng/mL and 7,930 ng h/mL, respectively). In contrast, the highest values for the maximum concentration and AUC in the livers were seen with 2-mercaptobenzimidazole (2,550 ng/mL and 11,600 ng h/mL, respectively), which also had the lowest hepatic LOEL value in this group. Further analysis showed that the LOEL values given in the HESS database and the hepatic AUC values that we obtained from the PBPK modeling were inversely correlated (*r* = −0.78, *p* \< 0.05, n = 7). This significant example indicated the importance of simulating the hepatic levels of general chemicals because those with high hepatic concentrations are more likely to be potent hepatotoxic compounds.

CONCLUSION AND FUTURE STUDY
===========================

In this review, the broad chemical diversity of the substances tested is illustrated in a two-dimensional plane depicting the chemical space ([Fig. 2](#f2-tr-35-295){ref-type="fig"}). We determined the permeability across the intestinal epithelial cell monolayers (in a pH-dependent Caco-2 cell system) of a diverse range of industrial chemicals/drugs. These permeability values provided a good estimation of oral absorbance as a putative marker of hepatotoxicity. Further analysis revealed that the cell permeability coefficients of the industrial chemicals were inversely correlated to their hepatic NOELs ([Fig. 3](#f3-tr-35-295){ref-type="fig"}), suggesting that the estimation of oral absorbance could be a useful tool to indicate hepatotoxicity *in vivo*. Moreover, the hepatic LOELs of chemicals and the virtual hepatic AUCs derived using PBPK modeling were also inversely correlated ([Table 2](#t2-tr-35-295){ref-type="table"}). Therefore, using PBPK models to estimate hepatic chemical concentrations following oral administration could also be useful as an indicator of hepatotoxicity *in vivo*. The present simplified PBPK models could estimate the relationships between hepatic/plasma concentrations of chemicals and their oral doses using both forward and reverse dosimetry and provide a useful approach to predict hepatotoxicity. Estimation of the parameters for simplified PBPK modeling ([Fig. 4B](#f4-tr-35-295){ref-type="fig"}) of additional chemicals will be carried out in future research projects by our research group. To develop a more precise hepatotoxicity prediction system based on PBPK modeling, it would be valuable to establish supportive equations to predict the key parameters for this simple PBPK modeling approach. In future, in-depth forward and reverse dosimetry assessments of industrial chemical levels would be facilitated by adopting more human PBPK models ([@b9-tr-35-295],[@b32-tr-35-295]) based on the above-described animal PBPK modeling techniques. In conclusion, evaluation of chemical exposure levels in the liver after oral doses should be one of the key primary steps, and mechanistic metabolic activations and their modifications ([@b33-tr-35-295]) will be critical to understanding the potential risk from multiple exposures ([@b34-tr-35-295]) in the field of chemical toxicology.
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![Apparatus for intestinal epithelial permeability testing. The Caco-2 cell monolayer system was used for a variety of general chemicals.](tr-35-295f1){#f1-tr-35-295}

![Coordinate values in a two-dimensional plane illustrating a variety of chemical structures. The density of the circles indicates apparent permeability values of the chemicals across an intestinal epithelial cell monolayer.](tr-35-295f2){#f2-tr-35-295}

![The inverse relationship between hepatic NOEL values of the industrial chemicals reported in a rat database and the apparent permeability data measured using Caco-2 permeability assays.](tr-35-295f3){#f3-tr-35-295}

![Schematic representations of one-compartment (A) and PBPK (B) models to simulate virtual oral administrations of the chemicals. *F*, *F*~a~, and *F*~g~: bioavailability, *k*~1~, and *k*~a~: absorption constants, *V*, *V*~1~, and *V*~h~: volumes of distribution, *k*~el~: elimination constant, and *CL*~h~ and *CL*~r~: clearances.](tr-35-295f4){#f4-tr-35-295}

###### 

Names of the chemicals tested in the current PBPK modeling

  --------------- --------------------------------- ------------------------------ ---------------------------------- ------------------------
  Acetaminophen   Chlorpyrifos                      Itopride                       Omeprazole                         Thalidomide
  Acrylonitrile   *m*-Cresol                        Lenalidomide                   Oseltamivir                        Tolbutamide
  Alprazolam      *p*-Cresol                        Losartan                       Paraacetaldehyde                   Toluene
  Aniline         Dabigatran                        Melengestrol acetate           Pemafibrate                        Trichloroethylene
  Apixaban        Dextromethorphan                  2-Mercaptobenzimidazole        PF-04937319                        Trimethylamine
  Apomorphine     Dichlorodiphenyltrichloroethane   Metoprolol                     Pomalidomide                       1,2,3-Trimethylbenzene
  Atomoxetine     Dichloromethane                   Midazolam                      Rivaroxaban                        1,2,4-Trimethylbenzene
  Azithromycin    1,4-Dioxane                       Molinate                       Styrene                            Verapamil
  Benzydamine     Disopyramide                      Mono(2-ethylhexyl) phthalate   Tetrabromobisphenol A              Warfarin
  Bisphenol A     Edoxaban                          Nicotine                       2,3,5,6-Tetrafluorobenzylalcohol   
  Caffeine        Fluvoxamine                       4-Nonylphenol                  Tetramethylammonium                
  --------------- --------------------------------- ------------------------------ ---------------------------------- ------------------------

These chemicals are those examined in our previous report ([@b15-tr-35-295]).

###### 

PBPK parameters and modeling results of seven compounds after virtual oral administration (1.0 mg/kg) and their reported hepatic NOEL and LOEL values in rats

  Substrate                 CAS No.      Log *P*~app~   PBPK parameters   PBPK modeling results   NOEL LOEL                                      
  ------------------------- ------------ -------------- ----------------- ----------------------- ----------- ------ ------ ------ ------- ----- -----
  2-Mercaptobenzimidazole   583-39-1     2.8            1.9               1.6                     0.1         172    2500   2550   11600   2     10
  4-Nonylphenol             84852-15-3   NA             1.4               1.2                     48.4        203    1350   2440   6570    15    250
  Paraacetaldehyde          123-63-7     NA             2.9               0.2                     0.1         1070   7930   840    5960    100   300
  1,2,3-Trimethylbenzene    526-73-8     NA             1.4               1.6                     7.3         30     180    630    1130    30    300
  1,2,4-Trimethylbenzene    95-63-6      NA             1.5               1.7                     7.6         29     175    683    1110    100   300
  *m*-Cresol                108-39-4     2.9            2.9               0.1                     2.0         459    421    913    668     100   300
  Bisphenol A               80-05-7      2.5            3.5               2.6                     62.4        15     66     1070   373     200   600

NA, not available. Data were obtained from our previous report ([@b15-tr-35-295]).
